Aarti Pharmalabs declares interim dividend of ₹1.5 per share; Record date Feb 16
Aarti Pharmalabs declared an interim dividend of ₹1.50 per equity share for FY25-26. The record date for dividend payment is February 16, 2026. The Board also approved the unaudited financial results for the quarter and nine months ended December 31, 2025.
The dividend declaration directly benefits shareholders. The financial results provide an update on the company's performance.
The declaration of an interim dividend is a positive indicator for shareholders.
Aarti Pharmalabs Limited announced the outcome of its Board Meeting held on February 09, 2026. The Board approved the unaudited financial results for the quarter and nine months ended December 31, 2025, along with the auditor's report.
Additionally, the Board declared an interim dividend of ₹1.50 per equity share (30%) for the Financial Year 2025-26. The face value of each equity share is ₹5. The company has fixed Monday, February 16, 2026, as the 'Record Date' for the purpose of payment of this interim dividend.
The Board meeting commenced at 2:00 p.m. and concluded at 7:00 p.m. The financial results are available on the company's website.
What to do with a filing like this
Aarti Pharmalabs Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.